1. Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance
- Author
-
Kyle Christian Hardy, Ravi Chakra Turaga, Zhi-Ren Liu, Malvika Sharma, Weike Li, Xin Li, Ming Luo, Zahra Enadi, Daping Fan, Falguni Mishra, Jun Tsao, and Sydney Nicole Dunham Tompkins
- Subjects
0301 basic medicine ,Cancer Research ,biology ,viruses ,Transgene ,Endogeny ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,biology.organism_classification ,lcsh:RC254-282 ,Article ,Virus ,Oncolytic virus ,Tumor resistance ,HeLa ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Apoptosis ,Vesicular stomatitis virus ,030220 oncology & carcinogenesis ,Cancer research ,Molecular Medicine ,Pharmacology (medical) - Abstract
Despite reports of successful clinical cases, many tumors appear to resist infection by oncolytic viruses (OVs). To circumvent this problem, an armed vesicular stomatitis virus was constructed by inserting a transgene to express Smac/DIABLO during virus infection (VSV-S). Endogenous Smac in HeLa cells was diminished during wtVSV infection, whereas the Smac level was enhanced during VSV-S infection. Apoptosis was readily induced by VSV-S, but not wtVSV, infection. More importantly, the tumor volume was reduced to a larger extent when xenografts of 4T1 cells in BALB/c mice and OV-resistant T-47D cells in nude mice were intratumorally injected with VSV-S. VSV-S represents a novel mechanism to overcome tumor resistance, resulting in more significant tumor regression due to enhanced apoptosis.
- Published
- 2019
- Full Text
- View/download PDF